(Q36929714)

English

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

scientific article published on 14 October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase II clinical trial

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

object named as

Jane N Winter

9

0 references

object named as

Chitra M Hosing

13

0 references

object named as

Leo I Gordon

24

0 references

Hillard M. Lazarus

16

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

12

object named as

David A Rizzieri

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edmund K Waller

22

object named as

Edmund K Waller

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Steven M Devine

4

object named as

Steven M Devine

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Philippe Armand

1

object named as

Philippe Armand

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Arnon Nagler

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edie A Weller

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David E Avigan

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yi-Bin Chen

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Mark S Kaminski

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

H Kent Holland

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

James R Mason

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Joseph W Fay

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Edward D Ball

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Joseph P Uberti

15

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Markus Y Mapara

17

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Stephanie A Gregory

18

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

John M Timmerman

19

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

David Andorsky

20

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Reuven Or

21

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Rinat Rotem-Yehudar

23

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

14 October 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

31

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

33

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

4199-4206

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

The PD-1 pathway in tolerance and autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Immune reconstitution after autologous hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

29 September 2017

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 September 2018

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4878008

4 December 2018

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with BAT monoclonal antibody decreases tumor burden in a murine model of leukemia/lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24127452

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2012.48.3685

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36929714&oldid=2133323186"